HUP0303126A2 - Vektorok molekuláknak CD11b-t expresszáló sejtekhez történő szállítására - Google Patents

Vektorok molekuláknak CD11b-t expresszáló sejtekhez történő szállítására

Info

Publication number
HUP0303126A2
HUP0303126A2 HU0303126A HUP0303126A HUP0303126A2 HU P0303126 A2 HUP0303126 A2 HU P0303126A2 HU 0303126 A HU0303126 A HU 0303126A HU P0303126 A HUP0303126 A HU P0303126A HU P0303126 A2 HUP0303126 A2 HU P0303126A2
Authority
HU
Hungary
Prior art keywords
expressing cells
vectors
cd11b
molecule delivery
adenyl cyclase
Prior art date
Application number
HU0303126A
Other languages
English (en)
Inventor
Cécile Bauche
Mohammed El-Azami El-Idrissi
Catherine Fayolle
Pierre Guermonprez
Nicole Guiso
Nadia Khelef
Daniel Ladant
Claude Leclerc
Original Assignee
Centre National De La Recherche Scientifique (C.N.R.S.)
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National De La Recherche Scientifique (C.N.R.S.), Institut Pasteur filed Critical Centre National De La Recherche Scientifique (C.N.R.S.)
Publication of HUP0303126A2 publication Critical patent/HUP0303126A2/hu
Publication of HUP0303126A3 publication Critical patent/HUP0303126A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y406/00—Phosphorus-oxygen lyases (4.6)
    • C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
    • C12Y406/01001—Aodenylate cyclase (4.6.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A találmány tárgyát képezi Bordetella fajból származó adenil-ciklázalkalmazása egy adott molekulának specifikusan CD11b-t expresszálósejtekhez történő irányításra szolgáló fehérjejellegű vektorelőállítására. A találmány tárgyát képezi továbbá a Bordetella eredetűadenil-cikláz-toxint tartalmazó immunogén és/vagy gyógyászatikészítmény, valamint a Bordetella eredetű adenil-cikláz-toxinttartalmazó, egy adott molekulának specifikusan CD11b-t expresszálósejtekhez történő irányításra szolgáló fehérjejellegű vektor. Ó
HU0303126A 2000-09-15 2001-09-14 Vectors for molecule delivery to cd11b expressing cells HUP0303126A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00402562A EP1188446B1 (en) 2000-09-15 2000-09-15 Proteinaceous vectors for molecule delivery to CD11b expressing cells
PCT/EP2001/011315 WO2002022169A2 (en) 2000-09-15 2001-09-14 VECTORS FOR MOLECULE DELIVERY TO CD11b EXPRESSING CELLS

Publications (2)

Publication Number Publication Date
HUP0303126A2 true HUP0303126A2 (hu) 2003-12-29
HUP0303126A3 HUP0303126A3 (en) 2004-10-28

Family

ID=8173866

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303126A HUP0303126A3 (en) 2000-09-15 2001-09-14 Vectors for molecule delivery to cd11b expressing cells

Country Status (17)

Country Link
US (4) US20040001867A1 (hu)
EP (2) EP1188446B1 (hu)
JP (1) JP2004508065A (hu)
KR (2) KR100953364B1 (hu)
AT (2) ATE438409T1 (hu)
AU (2) AU9385501A (hu)
BR (1) BR0113915A (hu)
CA (1) CA2422603A1 (hu)
CZ (1) CZ2003726A3 (hu)
DE (1) DE60042687D1 (hu)
ES (1) ES2331348T3 (hu)
HK (1) HK1057989A1 (hu)
HU (1) HUP0303126A3 (hu)
PL (1) PL208864B1 (hu)
PT (1) PT1188446E (hu)
RU (1) RU2312143C2 (hu)
WO (1) WO2002022169A2 (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646776B1 (fr) 1989-05-12 1994-06-03 Pasteur Institut Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella
DE60042687D1 (de) 2000-09-15 2009-09-17 Pasteur Institut Proteinhaltigen Vektoren zur Einführung von Moleküle in CD11b exprimirende Zellen
EP1489092A1 (en) 2003-06-18 2004-12-22 Institut Pasteur Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof
WO2005035557A2 (en) * 2003-10-14 2005-04-21 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Adenylate cyclase in the treatment and/or prophylaxis of immune-medicated disease
ES2337694T3 (es) * 2003-11-21 2010-04-28 Institut Pasteur Toxina de adenilato ciclasa recombinante de bordetella que induce las respuestas de la celula t contra los antigenos tumorales.
DK1576967T3 (da) 2004-03-18 2008-01-21 Pasteur Institut Rekombinant protein, der bærer epitoper fra det humane papillomvirus indsat i et adenylatcyclaseprotein eller et fragment deraf samt dets terapeutiske anvendelse
ES2291071B1 (es) 2005-06-13 2009-03-16 Proyecto De Biomedicina Cima, S.L. Agentes y metodos basados en el uso del dominio eda de la fibronectina.
ES2331271B1 (es) * 2007-06-29 2010-10-14 Universidad Del Pais Vasco Metodo para la internalizacion de bacterias no invasivas en celulas eucariotas.
US20110117578A1 (en) * 2008-05-29 2011-05-19 Bruce Acres Biomarker for selecting patients and related methods
CN102439146A (zh) * 2009-03-23 2012-05-02 巴斯德研究院 适合将免疫原性分子递送到细胞中的突变CyaA多肽及多肽衍生物
ES2505324T3 (es) 2009-03-23 2014-10-09 Institut Pasteur Polipéptidos de CyaA mutantes y derivados polipeptídicos adecuados para el suministro de moléculas inmunogénicas a una célula
GB201003920D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
EP2478915A1 (en) * 2011-01-24 2012-07-25 Genticel CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses
EP2689786A1 (en) 2012-07-23 2014-01-29 Genticel HPV/CYAA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders
EP2690172A1 (en) 2012-07-23 2014-01-29 Genticel CYAA-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses
EP2975120A1 (en) 2014-07-17 2016-01-20 Institut Pasteur Monomeric and functional adenylate cyclase CyaA toxin
WO2018091613A1 (en) 2016-11-17 2018-05-24 Ecole Nationale Vétérinaire de Toulouse Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection
EP3323426A1 (en) 2016-11-17 2018-05-23 Ecole Nationale Vétérinaire de Toulouse Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection
EP3342421A1 (en) 2016-12-27 2018-07-04 Genticel Immunogenic composition comprising cyaa-derived polypeptide promoting a th1/th17-oriented immune response
WO2019177669A1 (en) * 2017-11-03 2019-09-19 Mackay Memorial Hospital Method for modulation of tumor associated myeloid cells and enhancing immune checkpoint blockade

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601679B1 (fr) * 1986-07-15 1990-05-25 Sanofi Sa Immunotoxines, procede de preparation et compositions pharmaceutiques en contenant
US5182211A (en) 1987-08-07 1993-01-26 Institut Pasteur Plasmid vectors encoding a protein of a picornavirus
US5312902A (en) 1988-06-09 1994-05-17 Institut Pasteur Dimer of the precursor of HIV-2 envelope glycoprotein
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FR2638169B1 (fr) 1988-10-25 1991-01-11 Pasteur Institut Derives d'adenyl cyclase et leurs utilisations biologiques
EP0406857B1 (en) 1989-07-07 1995-05-24 Takeda Chemical Industries, Ltd. Proteins and production thereof
NO175188C (no) 1990-06-27 1994-09-14 Sjur Olsnes Fremgangsmåte for fremstilling av et peptidkonjugat med evne til å trenge inn i cellecytosol
US5935580A (en) * 1992-04-21 1999-08-10 Institut Pasteur Recombinant mutants for inducing specific immune responses
EP1715047A3 (en) * 1992-04-21 2008-08-27 Institut Pasteur Recombinant mutants for inducing specific immune responses
US5821122A (en) 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
JP4256932B2 (ja) * 1995-06-07 2009-04-22 ジョエル ケイ． スワデッシュ 抗原プロセシング細胞標的複合体
AU2322097A (en) 1996-03-27 1997-10-17 Ortho Pharmaceutical Corporation Lyophilized pulmonary surfactant peptide compositions
US6333154B1 (en) * 1997-12-04 2001-12-25 Institut Pasteur Bacterial multi-hybrid system and applications thereof
US6673914B1 (en) 1998-01-22 2004-01-06 John Wayne Cancer Institute Human tumor-associated gene
MXPA01011250A (es) * 1999-05-06 2002-08-12 Univ Wake Forest Composiciones y metodos para identificar antigenos que producen una respuesta inmune.
CN1402782A (zh) 1999-10-19 2003-03-12 路德维哥癌症研究院 Mage－a12抗原肽及其应用
DE60042687D1 (de) * 2000-09-15 2009-09-17 Pasteur Institut Proteinhaltigen Vektoren zur Einführung von Moleküle in CD11b exprimirende Zellen
EP1489092A1 (en) * 2003-06-18 2004-12-22 Institut Pasteur Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof
WO2005035557A2 (en) 2003-10-14 2005-04-21 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Adenylate cyclase in the treatment and/or prophylaxis of immune-medicated disease
ES2337694T3 (es) 2003-11-21 2010-04-28 Institut Pasteur Toxina de adenilato ciclasa recombinante de bordetella que induce las respuestas de la celula t contra los antigenos tumorales.
US20070026022A1 (en) 2004-11-19 2007-02-01 Gilles Dadaglio Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigens
DK1576967T3 (da) 2004-03-18 2008-01-21 Pasteur Institut Rekombinant protein, der bærer epitoper fra det humane papillomvirus indsat i et adenylatcyclaseprotein eller et fragment deraf samt dets terapeutiske anvendelse
EP1894941A1 (en) 2006-09-01 2008-03-05 Institut Pasteur Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying HPV antigens
US8017132B2 (en) * 2009-03-23 2011-09-13 Institut Pasteur Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell

Also Published As

Publication number Publication date
JP2004508065A (ja) 2004-03-18
DE60042687D1 (de) 2009-09-17
EP1317282B1 (en) 2011-08-03
EP1317282A2 (en) 2003-06-11
ATE518880T1 (de) 2011-08-15
CZ2003726A3 (cs) 2003-09-17
KR100953364B1 (ko) 2010-04-20
US9370564B2 (en) 2016-06-21
HK1057989A1 (en) 2004-04-30
PT1188446E (pt) 2009-11-10
AU9385501A (en) 2002-03-26
RU2312143C2 (ru) 2007-12-10
AU2001293855B2 (en) 2007-04-26
BR0113915A (pt) 2003-07-01
US10004794B2 (en) 2018-06-26
WO2002022169A2 (en) 2002-03-21
ATE438409T1 (de) 2009-08-15
HUP0303126A3 (en) 2004-10-28
US20050238637A1 (en) 2005-10-27
KR20080059684A (ko) 2008-06-30
PL208864B1 (pl) 2011-06-30
US20040001867A1 (en) 2004-01-01
ES2331348T3 (es) 2009-12-30
PL365743A1 (en) 2005-01-10
WO2002022169A3 (en) 2002-11-21
EP1188446A1 (en) 2002-03-20
KR20030055265A (ko) 2003-07-02
CA2422603A1 (en) 2002-03-21
KR100879151B1 (ko) 2009-01-19
EP1188446B1 (en) 2009-08-05
US20160375119A1 (en) 2016-12-29
US20120214206A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
HUP0303126A2 (hu) Vektorok molekuláknak CD11b-t expresszáló sejtekhez történő szállítására
HUP0203056A1 (hu) Vakcinakészítmény
NL300604I2 (hu)
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
NO20031646D0 (no) Ajuvantsammensetning omfattende et immunostimulatorisk oligonukleotid og entokol
HUP0302965A2 (hu) Vakcina
AU2002248384A1 (en) Serpin drugs for treatment of hiv infection and method of use thereof
CY1111431T1 (el) Μεταλλαγμενες πρωτεϊνες πλακουντιου αυξητικου παραγοντα τυπου 1, μεθοδος παρασκευης και εφαρμογες αυτων
YU68702A (sh) Novi lhrh-antagonisti, njihova proizvodnja i upotreba kao leka
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
DK0789764T3 (da) Ny familie af proteaseinhibitorer og andre biologisk aktive substanser
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
MXPA02012426A (es) Compuestos nuevos.
HUP0400840A2 (hu) Kis molekulatömegű hialuronsav immunogén készítményei, és eljárások A. csoportbeli és C. csoportbeli Streptococcusok által okozott fertőzések és betegségek megelőzéséhez, kezeléséhez és diagnózisához
AU6011001A (en) Novel lhrh-antagonists, production and use thereof as medicament
MXPA02012015A (es) Ligandos de receptores para integrinas.
DE60024977D1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
ATE380821T1 (de) Zytotoxische depsipeptide
BR0112486A (pt) Poliproteìna, molécula de ácido nucleico, plasmìdeo, vacina recombinante ou vacina atenuada, composição farmacêutica, e, método para imunizar um indivìduo contra hiv
WO2001074848A3 (en) Immunodominant acetylcholine receptor alpha subunit peptides, complexes thereof with mhc class ii components and their use
IL150979A0 (en) 9-alkylamino-1-nitroacridine derivatives
SE0002330D0 (sv) Novel compounds
WO2002008393A3 (en) Serine protease from yersinia enterocolitica

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees